Brief: Pardes Biosciences Announces FDA Clearance Of IND Application For PBI-0451
03/02/2022 12:02
Feb 3 (Reuters) - Pardes Biosciences Inc PRDS.O :
* PARDES BIOSCIENCES ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR PBI-0451, AN ORAL ANTIVIRAL DRUG CANDIDATE FOR THE TREATMENT
AND PREVENTION OF SARS-COV-2 INFECTIONS
* PARDES BIOSCIENCES INC - ANTICIPATE INITIATING OUR GLOBAL
PHASE
2/3 STUDIES OF PBI-0451 IN SARS-COV-2 INFECTED PATIENTS IN
MID-2022
Source text for Eikon: ID:nGNX6FTHgj
Further company coverage: PRDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pardes Biosciences
See all newsBrief: Pardes Biosciences Inc - Total Cash Amount That Medipacific Sub, Inc. Will Pay Pursuant To Terms Of Offer And Merger Agreement Is $2.13 Per Share
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Pardes Biosciences up on buyout deal with MediPacific
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Pardes Biosciences gains on buyout deal with MediPacific